Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LQDA NASDAQ:LUNG NASDAQ:SGHT NASDAQ:TCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia Technologies$15.71+4.0%$14.85$8.26▼$19.41$1.35B-0.011.31 million shs521,610 shsLUNGPulmonx$3.36+5.5%$2.99$2.50▼$9.37$133.66M0.45313,921 shs37,809 shsSGHTSight Sciences$3.50+2.0%$3.80$2.03▼$8.45$179.92M2.47206,173 shs4,197 shsTCMDTactile Systems Technology$9.94+2.9%$10.01$8.61▼$21.10$231.36M0.95250,186 shs31,588 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia Technologies+3.85%+4.28%+14.65%+11.93%+36.28%LUNGPulmonx+0.95%+18.66%+21.37%-33.19%-59.85%SGHTSight Sciences-2.00%-7.30%-15.52%+14.72%-54.93%TCMDTactile Systems Technology+1.47%-3.78%-3.11%-30.00%-21.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLQDALiquidia Technologies3.2551 of 5 stars4.50.00.00.01.84.20.6LUNGPulmonx3.104 of 5 stars3.35.00.00.00.63.30.6SGHTSight Sciences1.5753 of 5 stars2.12.00.00.01.83.30.6TCMDTactile Systems Technology3.1531 of 5 stars3.02.00.00.00.62.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLQDALiquidia Technologies 3.00Buy$26.8971.16% UpsideLUNGPulmonx 2.63Moderate Buy$11.53243.52% UpsideSGHTSight Sciences 2.29Hold$3.9312.41% UpsideTCMDTactile Systems Technology 2.00Hold$16.0060.95% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, TCMD, SGHT, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/2/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025LQDALiquidia TechnologiesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.005/28/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.005/28/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025LQDALiquidia TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.005/27/2025LQDALiquidia TechnologiesBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLQDALiquidia Technologies$14M95.93N/AN/A$0.91 per share17.26LUNGPulmonx$83.79M1.61N/AN/A$2.17 per share1.55SGHTSight Sciences$79.87M2.26N/AN/A$1.72 per share2.03TCMDTactile Systems Technology$293.16M0.79$1.13 per share8.80$9.03 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLQDALiquidia Technologies-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)TCMDTactile Systems Technology$16.96M$0.6615.0811.83N/A5.52%8.41%6.10%8/4/2025 (Estimated)Latest LUNG, TCMD, SGHT, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025SGHTSight Sciences-$0.25N/AN/AN/A$18.18 millionN/A8/6/2025Q2 2025LQDALiquidia Technologies-$0.43N/AN/AN/A$3.90 millionN/A8/4/2025Q2 2025TCMDTactile Systems Technology$0.09N/AN/AN/A$73.93 millionN/A7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/8/2025Q1 2025LQDALiquidia Technologies-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million5/5/2025Q1 2025TCMDTactile Systems Technology-$0.07-$0.13-$0.06-$0.13$63.48 million$61.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLQDALiquidia TechnologiesN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATCMDTactile Systems TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLQDALiquidia Technologies2.082.932.91LUNGPulmonx0.384.974.29SGHTSight Sciences0.5110.479.99TCMDTactile Systems Technology0.114.523.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLQDALiquidia Technologies64.54%LUNGPulmonx91.04%SGHTSight Sciences55.51%TCMDTactile Systems Technology83.43%Insider OwnershipCompanyInsider OwnershipLQDALiquidia Technologies30.10%LUNGPulmonx6.80%SGHTSight Sciences28.90%TCMDTactile Systems Technology2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLQDALiquidia Technologies5085.49 million59.75 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableSGHTSight Sciences21051.70 million36.76 millionOptionableTCMDTactile Systems Technology1,03723.25 million22.67 millionOptionableLUNG, TCMD, SGHT, and LQDA HeadlinesRecent News About These CompaniesTactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025July 21 at 4:05 PM | globenewswire.com3 Small Caps Drawing Insider and Institutional Support (TCMD)...July 14, 2025 | marketbeat.comTCMD Tactile Systems Technology, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comTactile Systems Technology (NASDAQ:TCMD) investors are sitting on a loss of 76% if they invested five years agoJune 23, 2025 | finance.yahoo.comNew Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer SurvivorsJune 3, 2025 | globenewswire.comTactile Medical to Present at Upcoming Investor Conferences in JuneMay 20, 2025 | globenewswire.comTactile Systems Technology, Inc. (NASDAQ:TCMD) CFO Sells $29,034.74 in StockMay 15, 2025 | insidertrades.comTactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole PictureMay 13, 2025 | finance.yahoo.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $31,911.00 in StockMay 10, 2025 | insidertrades.comPiper Sandler Downgrades Tactile Systems Technology (TCMD)May 8, 2025 | msn.comAnalysts Have Been Trimming Their Tactile Systems Technology, Inc. (NASDAQ:TCMD) Price Target After Its Latest ReportMay 7, 2025 | finance.yahoo.comWhy Tactile Systems Technology, Inc.’s (TCMD) Stock Is Down 33.21%May 6, 2025 | aaii.comATactile Systems stock tumbles after Q1 missMay 6, 2025 | investing.comTactile Systems downgraded to Neutral from Overweight at Piper SandlerMay 6, 2025 | msn.comTactile Systems Technology, Inc. (TCMD) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comWith 81% institutional ownership, Tactile Systems Technology, Inc. (NASDAQ:TCMD) is a favorite amongst the big gunsMay 5, 2025 | uk.finance.yahoo.comTactile Systems Technology (TCMD) Reports Q1 Loss, Lags Revenue EstimatesMay 5, 2025 | zacks.comTactile Systems Technology, Inc. Reports First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comWhat To Expect From Tactile Systems Technology Inc (TCMD) Q1 2025 EarningsMay 3, 2025 | finance.yahoo.comTactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025April 21, 2025 | globenewswire.comTactile Systems Technology: Interesting Devices Company, Need More ClarityApril 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUNG, TCMD, SGHT, and LQDA Company DescriptionsLiquidia Technologies NASDAQ:LQDA$15.71 +0.61 (+4.04%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Pulmonx NASDAQ:LUNG$3.36 +0.18 (+5.50%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Sight Sciences NASDAQ:SGHT$3.50 +0.07 (+2.01%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Tactile Systems Technology NASDAQ:TCMD$9.94 +0.28 (+2.91%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors TSLA Earnings Week: Can Tesla Break Through $350? D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike? Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.